Drugs / 13C Cholate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03294941 | Dec 2017 → Sep 2019 | metabolic dysfunction-associated steatohepatitis | HepQuant, LLC | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02523196 | Mar 2016 → Feb 2017 | liver disorder | University of Colorado, Denver | Completed | No outcome recorded |
| Phase not applicable1 trial · 1 met primary | ||||||
| — | NCT03583996 | Jan 2019 → May 2021 | liver disorder | HepQuant, LLC | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13C-cholate | “HepQuant SHUNT is a combination product where 13C Cholate 20mg is administered intravenously once for each test” NCT03294941 ↗ |
| Route | Intravenous | “13C Cholate 20mg is administered intravenously once for each test” NCT03294941 ↗ |